References

The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide

10.1002/ijc.35278 · 2025 · External reference

Hepatocellular Carcinoma

10.1016/j.cnc.2022.04.004 · 2022 · External reference

Liver cancer incidence and mortality in China: temporal trends and projections to 2030

10.21147/j.issn.1000-9604.2018.06.01 · 2018 · External reference

AASLD Guidelines for the Treatment of Hepatocellular Carcinoma

10.1002/hep.29086 · 2018 · External reference

committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan. Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines)

10.1111/hepr.13892 · 2023 · External reference

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma

10.1016/j.jhep.2024.08.028 · 2025 · External reference

Clinical Practice Guidelines for the Diagnosis and Treatment of Primary Hepatocellular Carcinoma (2024 Version)

2024 · External reference

Assessing the impact and resource implications of contrast-enhanced ultrasound on workflow of patients with incidental focal liver lesions on the UK national health service

2023 · External reference

A qualitative signature for early diagnosis of hepatocellular carcinoma based on relative expression orderings

10.1111/liv.13864 · 2018 · External reference

Introduction: 4th Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver—Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM and FLAUS

10.1016/j.ultrasmedbio.2020.08.015 · 2020 · External reference

Diagnostic accuracy of CEUS LI-RADS for the characterization of liver nodules 20 mm or smaller in patients at risk for hepatocellular carcinoma

10.1148/radiol.2019191086 · 2020 · External reference

Evaluation of contrast-enhanced US LI-RADS version 2017: application on 2020 liver nodules in patients with hepatitis B infection

10.1148/radiol.2019190878 · 2020 · External reference

CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI

10.1007/s00261-017-1250-0 · 2018 · External reference

Contrast enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS): the official version by the American College of Radiology (ACR)

10.1055/s-0042-124369 · 2017 · External reference

CEUS LI-RADS Italy study group collaborators: Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter retrospective study of 1,006 nodules

10.1016/j.jhep.2017.11.007 · 2018 · External reference

CEUS LI-RADS for diagnosis of hepatocellular carcinoma in individuals without LI-RADS-defined hepatocellular carcinoma risk factors

10.1186/s40644-023-00541-2 · 2023 · External reference

Contrast enhanced ultrasound liver imaging reporting and data system in diagnosing hepatocellular carcinoma: diagnostic performance and interobserver agreement

2020 · External reference

Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis

10.1007/s00330-022-08872-7 · 2022 · External reference

The Value of CEUS LI-RADS combined with AFP in early diagnosis of hepatocellular carcinoma in low- and high-risk patients

10.4103/jcrt.jcrt_125_24 · 2024 · External reference

Combining serum AFP and CEUS LI-RADS for better diagnostic performance in Chinese high-risk patients

10.1007/s11547-023-01614-9 · 2023 · External reference

CT/MR LI-RADS 2018: clinical implications and management recommendations

10.1007/s00261-018-1868-6 · 2019 · External reference

Enhancement patterns of small hepatocellular carcinoma (≤30 mm) on contrast-enhanced ultrasound: Correlation with clinicopathologic characteristics

2022 · External reference

Characteristics of contrast-enhanced ultrasound in distinguishing small (≤3 cm) hepatocellular carcinoma from intrahepatic cholangiocarcinoma

10.1097/md.0000000000012781 · 2018 · External reference

NAFLD-driven HCC: safety and efficacy of current and emerging treatment options

10.1016/j.jhep.2021.09.007 · 2022 · External reference

Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis

10.1111/liv.14087 · 2019 · External reference

Comparison of machine learning models and CEUS LI-RADS in differentiation of hepatic carcinoma and liver metastases in patients at risk of both hepatitis and extrahepatic malignancy

2023 · External reference

Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma

10.1016/j.ejrad.2022.110415 · 2022 · External reference

Alpha-foetoprotein (AFP): a multi-purpose marker in hepatocellular carcinoma

10.1016/j.cca.2016.10.006 · 2016 · External reference

An assessment of liver lesions using a combination of CEUS LI-RADS and AFP

10.1007/s00261-022-03428-1 · 2022 · External reference

US LI-RADS in surveillance for recurrent hepatocellular carcinoma after curative treatment

10.1007/s00330-023-09903-7 · 2023 · External reference

The role of contrast-enhanced ultrasound in the evaluation of hepatobiliary lesions and its correlation with pathological findings

10.5114/pjr.2022.123563 · 2022 · External reference

Diagnostic performance and interreader agreement of CEUS LI-RADS in ≤ 30 mm liver nodules with different experienced radiologists

10.1007/s00261-022-03468-7 · 2022 · External reference

Inter-reader agreement of CEUS LI-RADS among radiologists with different levels of experience

10.1007/s00330-021-07777-1 · 2021 · External reference

Comparison of modified CEUS LI-RADS with sonazoid and CT/MRI LI-RADS for diagnosis of hepatocellular carcinoma

10.1111/hepr.13793 · 2022 · External reference

Diagnostic value of CEUS LI-RADS Version 2017 in differentiating AFP-negative hepatocellular carcinoma from other primary malignancies of the liver

10.3390/diagnostics11122250 · 2021 · External reference